ISRCTN51367236
Completed
Not Applicable
The effects of medical therapy on insulin resistance and the cardiovascular system in PolyCystic Ovarian Syndrome
Southern Health (Australia)0 sites110 target enrollmentApril 3, 2006
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Southern Health (Australia)
- Enrollment
- 110
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Overweight women (body mass index \[BMI] greater than 27 kg/m^2\)
- •2\. Aged 18 \- 40 years with PCOS diagnosed from a history of perimenarchal onset of irregular cycles (less than 21 days or greater than 35 days) plus clinical manifestations of hyperandrogenism (hirsutism, acne) or biochemical hyperandrogenism with elevation of at least one circulating ovarian androgen (1990 National Institute of Health \[NIH] criteria)
Exclusion Criteria
- •1\. BMI less than 27 kg/m^2
- •2\. Other concurrent medical conditions
- •3\. Ongoing use of the OCP
- •4\. Pregnancy or desire for pregnancy
- •4\. Secondary causes of amenorrhoea and hyperandrogenism
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
A study on the effects of insulin resistance on the effects of insulin resistance on endometrial receptivity in the treatment of spleen and kidney deficiency and yang and yang turbidity fever syndromePCOSITMCTR2024000014Beijing Hospital of Traditional Chinese Medicine, Capital Medical University
Completed
Phase 4
Impact on insulin sensitivity and insulin resistance after the conversion from tacrolimus twice daily to extended-release tacrolimus once daily in stable renal transplant recipientsinsulin sensitivityinsulin resistanceinsulin sensitivityinsulin resistancetacrolimusextended release tacrolimus once dailyTCTR20151005001Prajej Ruangkanchanasetr28
Active, not recruiting
Not Applicable
Insuline resistance treatment effect in patients with genotype 1 hepatitis C treated with peginterferon alfa-2a plus ribavirin in usual clinical practiceEfecto del tratamiento de la resistencia a insulina en los pacientes con hepatitis C crónica genotipo 1 tratados con peginterferón alfa-2a en combinación con ribavirina en la práctica clínica habitual - Insuline resistance treatment effect in genotype 1 hepatitis C treated with Peg-IFN alfa 2a & RBVTreatment effect of insuline resistance in patients with genotype 1 hepatitis C treated with peginterferon alfa 2a plus ribavirin in usual clinical practiceEUCTR2005-002446-19-ESHospital de Valme
Active, not recruiting
Not Applicable
Clinical study on the insulin sensitizing effect of multiple administration of Vition (Meditop) in healthy human volunteers (Pilot study)EUCTR2011-001859-36-HUMeditop Pharmaceuticals Co. Ltd.
Completed
Not Applicable
Effect of insulin therapy and dietary adjustments on performance during simulated soccer tests in people with type 1 diabetesType 1 diabetesNutritional, Metabolic, EndocrineISRCTN17447843Asociación Nacional Pro Estudio de la Diabetes, Endocrinología y Metabolismo16